Regen BioPharma Inc (RGBP)

[cvinvestor]

Gut feeling is that somewhere along the line (May 2014 - Dec 2014), something significant happened, good or bad, which was the cause for the dramatic change in strategy for RGBP. The new lab is something I believe was planned and foreseen weeks ago in light of something that has taken place and which will slowly be unravelled in PRs to us over the course of the coming weeks/months.

Money raising/ hiring of scientists/ acquiring of patents/ pursuance of yet more products for IND while we finally know that HemaX is not dead, but will go forward, expanding to new law for Ichims to develop NR2F6 and the other IND candidate. All this becoming a seemingly new and urgent focus is for a reason.

New4This's link to Pfizer teaming with iTeos on a target of the endolamine 2,3 is significant as it parallels RGBP's specific target. For this I don't think it's a matter of who gets there first, as RGBP has patents in place, so treatments must be different in some aspect, but the fact Pfizer is paying to pursue treatment with the same target is noteworthy.

Someone else might be willing to pay to license a competitive treatment alongside Pfizer, i.e. from RGBP.